Helix Partners Exits Sallie Mae Position as Student Loan Servicer Faces Credit Headwinds

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Helix Partners exits entire Sallie Mae stake amid rising loan delinquencies and credit headwinds at the student loan servicer, which underperformed the market by 27.5 percentage points.

Helix Partners Exits Sallie Mae Position as Student Loan Servicer Faces Credit Headwinds

Helix Partners Management LP has liquidated its entire stake in SLM Corporation, selling 200,000 shares for approximately $5.54 million during the fourth quarter. The divestment occurs as Sallie Mae's stock has underperformed significantly, declining 14.6% over the past 12 months compared to a 13% gain in the S&P 500, representing a 27.5 percentage point gap in relative performance.

The fund's exit coincides with emerging credit challenges at the student loan servicer. SLM reported loan delinquencies rising to 4.0% and provided guidance indicating increased net charge-offs anticipated for 2026, suggesting a normalization of credit conditions following the extended federal student loan payment moratorium. These metrics contrast with the company's otherwise solid operational performance, which included $3.46 in GAAP diluted earnings per share in recent results.

Despite these headwinds, Sallie Mae's board authorized a $500 million share repurchase program, indicating management confidence in the company's long-term value. However, rising credit stress and elevated delinquency rates may limit stock appreciation near term as investors assess the trajectory of loan performance in a higher-rate environment.

Source: The Motley Fool

Back to newsPublished Feb 14

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO